Status In progress
Process STA 2018
ID number 1591

Provisional Schedule

Committee meeting: 2 16 September 2021
Expected publication 25 November 2021

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd

Consultees

Companies sponsors GlaxoSmithKline UK (Belimumab (Benlysta))
Others Department of Health and Social Care
Patient carer groups AOFAC Foundation
  Lupus UK
Professional groups British Association of Dermatologists
  British Society for Rheumatology
  Renal Association
  Royal College of Physicians

Commentators

Comparator companies Pfizer (cyclophosphamide)
  Roche Pharmaceuticals (rituximab)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  NHS England Specialised Rheumatology Clinical Reference Group
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
04 June 2021 - 25 June 2021 Appraisal consultation
12 May 2021 Committee meeting: 1
26 August 2020 Invitation to participate
10 June 2020 - 10 July 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
24 June 2020 In progress. Topic update: this appraisal has now been rescheduled into the work programme and is due to be discussed at committee on 5 May 2021.
05 May 2020 Schedule affected by COVID-19. Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
27 February 2020 In progress. Topic is in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance